ClinicalTrials.gg

Program

lysergide D-tartrate

Also written as “DT120” and “MM120”.

Its studies are mostly in Generalized Anxiety Disorder · Depressive Disorder, Major · Attention Deficit Disorder with Hyperactivity, led by Definium Therapeutics US.

Furthest: phase 3, since Dec 16, 20246 company-led studies, 4 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Definium Therapeutics US64 open or runningphase 3since Dec 16, 2024Dec 21, 2021Sep 2027phase 3 · NCT07592689

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2021First study: phase 2 study in Attention Deficit Disorder with HyperactivityFirst studyNCT05200936 · 53 enrolled · Netherlands, Switzerland
  2. May 27, 2022Phase 2 study in Generalized Anxiety DisorderNCT05407064 · 198 enrolled · United States
  3. Dec 16, 2024Phase 3 study in Generalized Anxiety DisorderNCT06741228 · 214 enrolled · United States
  4. Jan 30, 2025Phase 3 study in Generalized Anxiety DisorderNCT06809595 · 245 enrolled · United States, Czechia, France and more
  5. Apr 16, 2025Phase 3 study in Depressive Disorder, MajorNCT06941844 · 149 enrolled · United States
  6. May 12, 2026Phase 3 study in Depressive Disorder, MajorNCT07592689 · 165 planned · United States

Ahead

  1. Sep 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07592689

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07592689Depressive Disorder, Major · United States3RecruitingSep 2027165
NCT06941844Depressive Disorder, Major · United States3Active, not recruitingMay 20, 2026149
NCT06809595Generalized Anxiety Disorder · United States, Czechia, France and more3Active, not recruitingAug 13, 2026245
NCT06741228Generalized Anxiety Disorder · United States3Active, not recruitingJul 15, 2026214
NCT05407064Generalized Anxiety Disorder · United States2CompletedOct 6, 2023198
NCT05200936Attention Deficit Disorder with Hyperactivity · Netherlands, Switzerland2CompletedNov 6, 202353

How it is read

Names in the registry

  • “DT120”, 4 entries
  • “MM120”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
lysergide D-tartrate (Definium Therapeutics US): development program | ClinicalTrials.gg